T. Rowe Price Associates’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-106,908
| Closed | -$4.3M | – | 3245 |
|
|
2026
Q1 | $4.3M | Buy |
106,908
+11,873
| +12% | +$256K | ﹤0.01% | 1478 |
|
|
2025
Q4 | $2.39M | Sell |
95,035
-2,905
| -3% | -$68.2K | ﹤0.01% | 1675 |
|
|
2025
Q3 | $2.22M | Buy |
97,940
+5,789
| +6% | +$135K | ﹤0.01% | 1690 |
|
|
2025
Q2 | $1.6M | Buy |
92,151
+1,451
| +2% | +$26.9K | ﹤0.01% | 1751 |
|
|
2025
Q1 | $1.98M | Sell |
90,700
-267,878
| -75% | -$7.4M | ﹤0.01% | 1608 |
|
|
2024
Q4 | $11.4M | Sell |
358,578
-19,878
| -5% | -$598K | ﹤0.01% | 1132 |
|
|
2024
Q3 | $10.9M | Sell |
378,456
-897,970
| -70% | -$33.3M | ﹤0.01% | 1124 |
|
|
2024
Q2 | $49M | Sell |
1,276,426
-1,182,820
| -48% | -$53.6M | 0.01% | 733 |
|
|
2024
Q1 | $145M | Sell |
2,459,246
-1,093
| -0% | -$69.7K | 0.02% | 483 |
|
|
2023
Q4 | $147M | Buy |
2,460,339
+677,098
| +38% | +$34.3M | 0.02% | 472 |
|
|
2023
Q3 | $67.8M | Sell |
1,783,241
-5,288,985
| -75% | -$232M | 0.01% | 593 |
|
|
2023
Q2 | $644M | Buy |
7,072,226
+2,482,186
| +54% | +$214M | 0.09% | 215 |
|
|
2023
Q1 | $303M | Buy |
4,590,040
+1,840,498
| +67% | +$106M | 0.05% | 312 |
|
|
2022
Q4 | $142M | Sell |
2,749,542
-601,421
| -18% | -$31.9M | 0.02% | 435 |
|
|
2022
Q3 | $229M | Sell |
3,350,963
-5,328,850
| -61% | -$315M | 0.04% | 338 |
|
|
2022
Q2 | $393M | Buy |
8,679,813
+794,974
| +10% | +$36.2M | 0.05% | 335 |
|
|
2022
Q1 | $401M | Buy |
7,884,839
+2,586,348
| +49% | +$114M | 0.04% | 370 |
|
|
2021
Q4 | $251M | Buy |
5,298,491
+491,414
| +10% | +$19.3M | 0.02% | 499 |
|
|
2021
Q3 | $158M | Sell |
4,807,077
-363,417
| -7% | -$20.4M | 0.01% | 625 |
|
|
2021
Q2 | $327M | Buy |
5,170,494
+1,528,345
| +42% | +$78.9M | 0.03% | 438 |
|
|
2021
Q1 | $156M | Buy |
3,642,149
+596,820
| +20% | +$28.2M | 0.02% | 631 |
|
|
2020
Q4 | $174M | Buy |
3,045,329
+66,929
| +2% | +$2.83M | 0.02% | 558 |
|
|
2020
Q3 | $89.9M | Sell |
2,978,400
-49,435
| -2% | -$1.48M | 0.01% | 689 |
|
|
2020
Q2 | $98.9M | Buy |
3,027,835
+1,776,965
| +142% | +$57.1M | 0.01% | 641 |
|
|
2020
Q1 | $33.5M | Buy |
1,250,870
+459,207
| +58% | +$16.3M | 0.01% | 911 |
|
|
2019
Q4 | $24.2M | Sell |
791,663
-82,749
| -9% | -$2.29M | ﹤0.01% | 1124 |
|
|
2019
Q3 | $21.1M | Buy |
874,412
+175,200
| +25% | +$4.82M | ﹤0.01% | 1135 |
|
|
2019
Q2 | $17.7M | Buy |
699,212
+19,324
| +3% | +$393K | ﹤0.01% | 1210 |
|
|
2019
Q1 | $13.3M | Sell |
679,888
-38,995
| -5% | -$613K | ﹤0.01% | 1276 |
|
|
2018
Q4 | $9.48M | Sell |
718,883
-191,676
| -21% | -$2.94M | ﹤0.01% | 1320 |
|
|
2018
Q3 | $16.2M | Sell |
910,559
-51,124
| -5% | -$945K | ﹤0.01% | 1286 |
|
|
2018
Q2 | $21.2M | Buy |
+961,683
| New | +$22.1M | ﹤0.01% | 1181 |
|
Other funds holding APLS
T. Rowe Price Associates's APLS Position: Q2 2026 in Review
T. Rowe Price Associates sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 106,908 shares — an estimated $4.3M sold.
T. Rowe Price Associates first reported a position in APLS in Q2 2018 and held it in 32 quarters. The position peaked at $644M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- T. Rowe Price Associates reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- T. Rowe Price Associates sold 106,908 Apellis Pharmaceuticals shares in Q2 2026, an estimated $4.3M.
- T. Rowe Price Associates first reported a position in Apellis Pharmaceuticals in Q2 2018 and held it in 32 quarters.
- T. Rowe Price Associates's Apellis Pharmaceuticals position peaked at $644M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.